文献速递肿瘤 PET/CT核素与放射性配体治疗

[18F]PSMA-1007与[68Ga]Ga-PSMA-11 PET/CT在前列腺癌患者中的前瞻性个体内盲法比较

Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-08-12

本研究前瞻性纳入50例确诊前列腺癌男性,间隔<4周分别行[68Ga]Ga-PSMA-11与[18F]PSMA-1007 PET/CT,由核医学专家盲法按TNM独立报告。两种示踪剂总体AJCC预后分期一致率为92%(46/50),[18F]PSMA-1007在局部复发、淋巴结及远处转移和多数生理部位摄取更高,但膀胱摄取显著更低,且肝脏摄取掩盖了一例右侧肾上腺转移,并发现更多可疑骨病变。

要点

  • 两种PSMA示踪剂总体AJCC预后分期一致率为92%,但个别病例存在分期差异。
  • [18F]PSMA-1007在局部复发、淋巴结和远处转移及多数生理部位摄取更高。
  • [18F]PSMA-1007膀胱摄取显著更低,有助于前列腺原发/局部复发及邻近输尿管区域淋巴结分期。

核心结论

  • 两种示踪剂总体AJCC预后分期相似,一致率为92%(46/50)。
  • [18F]PSMA-1007在受累淋巴结、远处转移和多数生理部位摄取更高,但膀胱摄取显著更低。
  • [18F]PSMA-1007肝脏摄取掩盖了一例孤立的右侧肾上腺转移,且识别出更多可疑骨病变。

研究设计与样本

  • 前瞻性个体内盲法比较研究,纳入50例确诊前列腺癌男性,平均年龄71.8岁。
  • 患者间隔<4周分别行[68Ga]Ga-PSMA-11与[18F]PSMA-1007 PET/CT。
  • 图像由两名经验丰富的核医学专家盲法按TNM独立报告,分歧由第三名独立专家裁决。
  • 定量分析由一名经验丰富的阅片者完成,评估病灶摄取与生理组织摄取。

主要发现

  • 扫描指征包括初始分期(n=12)、生化复发(n=27)和转移性疾病评估(n=11)。
  • 多数患者ISUP分级组≥3,中位PSA为2.7 ng/ml(IQR 0.7-12.0),28%患者当时接受雄激素剥夺治疗。
  • [18F]PSMA-1007在局部复发、淋巴结转移、远处转移及多数生理部位(包括骨)摄取显著高于[68Ga]Ga-PSMA-11,膀胱摄取显著更低。
  • [18F]PSMA-1007使5/17例前列腺局部分期升级、3/33例局部复发升级、3/50例区域淋巴结升级及1例远处转移(膀胱)升级。
  • [68Ga]Ga-PSMA-11使1/50例区域淋巴结升级及1例远处转移(右肾上腺)升级。

关键数值与推荐

  • 总体AJCC预后分期一致率为92%(46/50)。
  • [18F]PSMA-1007使5/17例局部前列腺分期升级、3/33例局部复发升级、3/50例区域淋巴结升级及1例远处转移升级。
  • [68Ga]Ga-PSMA-11使1/50例区域淋巴结升级及1例远处转移升级。
  • [18F]PSMA-1007识别6个模棱两可骨病变(1个后续证实转移),[68Ga]Ga-PSMA-11识别1个模棱两可局部复发。

临床怎么用

  • 两种PSMA示踪剂总体预后分期高度一致,临床选择时可考虑其摄取特征差异。
  • [18F]PSMA-1007膀胱摄取低,可能有助于前列腺原发/局部复发及邻近输尿管区域淋巴结的评估。
  • 需注意[18F]PSMA-1007肝脏摄取可能掩盖肾上腺等部位转移,且骨病变模棱两可结果较多。

局限性

  • 样本量较小(50例),部分扫描指征亚组病例数有限。
  • 原文未报告诊断性能指标(如敏感性、特异性)及示踪剂间定量摄取差异的统计学检验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: [18F]PSMA-1007 has potential advantages over [68 Ga]Ga-PSMA-11, although limited prospective data evaluating diagnostic performance exist. The aims of this study are to describe the concordance of [18FPSMA-1007 and [68 Ga]Ga-PSMA-11 for TNM with the American Joint Committee on Cancer (AJCC) prognostic stage and assess differences in tracer uptake. METHODS: Fifty men (mean age 71.8) were imaged with [68 Ga]Ga-PSMA-11 and [18F]PSMA-1007 < 4 weeks apart. Images were independently reported according to TNM by two experienced nuclear medicine specialists blinded to the other scan and prior imaging. Discordant results were resolved by a third independent nuclear medicine specialist. Quantitative analysis of lesion uptake and physiologic tissue for each tracer was performed by one experienced reader. RESULTS: Scan indications were initial staging (n = 12), biochemical recurrence (n = 27) and metastatic disease evaluation (n = 11). Most patients had ISUP grade group 3 or higher. Median PSA value was 2.7 ng/ml (IQR 0.7-12.0), and a minority of patients (28%) were currently treated with androgen deprivation therapy. [18F]PSMA-1007 uptake was significantly higher than [68Ga]Ga-PSMA-11 in local recurrence, nodal and distant metastases and most physiologic sites (including bone) except for urinary bladder which was significantly lower. [18F]PSMA-1007 upstaged local prostate staging in 5/17 patients, local recurrence in 3/33 patients, regional nodal disease in 3/50 patients and 1 distant metastasis (bladder). [68Ga]Ga-PSMA-11 upstaged regional nodal disease in 1/50 patients and distant metastasis in one patient (right adrenal). Overall AJCC prognostic stage was concordant in 46/50 (92%) patients, with two patients upstaged for both [18F]PSMA-1007 and [68Ga]Ga-PSMA-11. [18F]PSMA-1007 had more equivocal results (one regional node; six equivocal bone lesions, one of which was subsequently confirmed metastatic) than [68Ga]Ga-PSMA-11 (one equivocal local recurrence). CONCLUSION: Overall AJCC prognostic stage was similar (92%) between [18F]PSMA-1007 and [68Ga]Ga-PSMA-11. [18F]PSMA-1007 demonstrates higher uptake within involved nodes and distant metastases and most physiologic sites except urinary bladder which aided [18F]PSMA-1007 local staging of the prostate primary/local recurrence and regional nodal disease adjacent ureters. However, [18F]PSMA-1007 liver uptake obscured a solitary right adrenal metastasis, and more equivocal bone lesions were identified. Trial registration The study was registered with Australia New Zealand Clinical Trials Registry (ACTRN12618000665235) on 24 April 2018.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Pattison DA, Debowski M, Gulhane B, et al. Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68 Ga]Ga-PSMA-11 PET/CT imaging in patients with confirmed prostate cancer. Eur J Nucl Med Mol Imaging. 2021. PMID: 34383089. doi:10.1007/s00259-021-05520-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。